最新一期业绩显示，2024年三季报，公司实现营业收入8.23亿元，同比-4.96%；净利润1038.55万元，同 比107.70%，销售毛利率50.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)19贝瑞基因-18.16-11.982.7351.19亿行业平均 45.1449.524.84107.93亿行业中值31.9931.002.4848.44亿1硕世生物-1949.53-1949.531.2340.28亿2诺唯 赞-562.38-562.382.4395.62亿3利德曼-363.03174.161.5426.71亿4博晖创新-300.71-185.143.3146.15亿5康泰 医学-292.3334.302.9956.86亿6华大基因-221.13241.882.29224.71亿7奥精医疗-121.20-121.201.5421.96亿8 睿昂基因-82.72-82.721.2911.96亿9华大智造-55.10-55.104.14330.13亿10中红医疗-54.40-37.010.8648.44亿 11天智航-46.36-46.364.8457.07亿 来源：金融界 贝瑞基因收盘 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-010 成都市贝瑞和康基因技术股份有限公司 关于与专业投资机构共同投资的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、投资概述 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）全资子公司福建 贝瑞和康基因技术有限公司（以下简称"福建贝瑞和康"）与上海致凯资产管理有 限公司、福州新投创业投资有限公司、上海润达医疗科技股份有限公司、上海福凯 瑞康企业管理咨询合伙企业（有限合伙）共同签署《福州新投致凯瑞康创业投资基 金合伙企业（有限合伙）合伙协议》，共同投资设立福州新投致凯瑞康创业投资基 金合伙企业（有限合伙）（以下简称"合伙企业"），合伙企业目标募资规模为人 民币13,400万元，其中福建贝瑞和康作为有限合伙人认缴出资2,680万元，占合伙 企业出资总额的20.00%。具体内容详见公司于2024年12月31日在巨潮资讯网披露的 《关于与专业投资机构共同投资的公告》（公告编号：2024-057）。 近日，公司收到合伙企业通知，该合伙企业已在中国证券投资基金业协会完成 备案手续，备案 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-009 成都市贝瑞和康基因技术股份有限公司 第十届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事 会第十二次会议于2025年3月24日在北京市昌平区生命园路4号院5号楼8层会议 室以现场与通讯会议相结合的方式召开，会议通知已于2025年3月21日以邮件形 式发送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信息。本 次董事会会议应出席董事7名，实际出席会议董事7名，会议由董事长高扬先生 主持，董事会秘书列席了会议。会议的召开和表决程序符合有关法律、行政法 规、部门规章、规范性文件和公司章程的规定。 2、审议通过《关于调整<第一期员工持股计划（草案）>及摘要的议案》 表决结果：7票同意，0票反对，0票弃权。 公司拟对《第一期员工持股计划（草案）》第六章"2、员工持股计划的锁 定期"、《第一期员工持股计划（草案）摘要》第六章"2、员工持股计划的锁 定期"进行调整。具体内容详见公司于202 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-007 成都市贝瑞和康基因技术股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 近日，成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"、"公司"） 之全资子公司北京贝瑞和康生物技术有限公司（以下简称"北京贝瑞"）向中国民生银 行股份有限公司北京分行申请综合授信 10,000 万元，授信期限 1 年。公司拟为北京贝瑞 使用上述授信所形成的债务提供连带责任保证担保，北京贝瑞以取得不动产权的位于昌 平区生命园路 4 号院 5 号楼的房产为使用上述授信所形成的债务提供抵押担保，公司控 股股东高扬先生及其一致行动人侯颖女士为该笔授信提供个人无限连带责任保证担保。 公司于 2025 年 3 月 24 日召开第十届董事会第十二次会议审议通过了《关于为全资 子公司提供担保的议案》。根据证监会《上市公司监管指引第 8 号——上市公司资金往 来、对外担保的监管要求》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市公 司自律监管指引第 1 号— ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-008 成都市贝瑞和康基因技术股份有限公司 关于调整第一期员工持股计划的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）于2025年3月 24日召开第十届董事会第十二次会议，审议通过了《关于调整<第一期员工持股 计划（草案）>及摘要的议案》《关于调整<第一期员工持股计划管理办法>的议 案》，现将相关情况公告如下： 公司于2024年3月29日召开第十届董事会第七次会议，审议通过了《关于第 一期员工持股计划存续期展期的议案》，同意将第一期员工持股计划的存续期延 长12个月，即存续期延长至2025年3月31日。具体内容详见公司于2024年3月30日 在巨潮资讯网披露的《关于第一期员工持股计划存续期展期的公告》。 二、第一期员工持股计划的调整原因及调整情况 根据公司《第一期员工持股计划（草案）》和《第一期员工持股计划管理办 法》的规定，在本员工持股计划存续期间，经持有人会议同意并提交公司董事会 审议通过后，员工持股计划可以变更。 根据中国证监会于 ...

Investment Rating - The industry investment rating is "Recommended" [1] Core Viewpoints - The report highlights a revolution in sequencing technology empowered by AI, with domestic companies accelerating their AI business layout [5][6] - The domestic sequencing market is rapidly growing, with China becoming the second-largest gene testing market globally, surpassing 33.5 billion RMB in 2024 [31] - AI technology is significantly reducing costs and enhancing the efficiency and accuracy of sequencing processes, leading to advancements in personalized treatment and drug development [32] Summary by Sections Industry Overview - The pharmaceutical and biotechnology industry includes 645 listed companies with a total share capital of 5,825.23 million shares and sales revenue of 37,462.19 billion RMB [1] - The total profit for the industry is 3,382.22 billion RMB, with an average PE ratio of 42.37 [1] Market Performance - The pharmaceutical index increased by 1.06% during the week of March 3-7, 2025, underperforming the CSI 300 index, which rose by 1.39% [7][9] - The pharmaceutical industry index PE (TTM, excluding negative values) is 26.65 times, with a valuation premium of 121.81% compared to the CSI 300 index, indicating a historical low [9] AI Empowerment in Sequencing Technology - AI is optimizing sequencing processes and data analysis algorithms, enhancing speed and accuracy [31] - Domestic companies like BGI and Tempus are leveraging AI to create closed-loop ecosystems for data analysis and clinical applications [20][21] - The report emphasizes the importance of AI in reducing detection costs and improving personalized treatment options [32] Key Companies and Developments - Tempus AI focuses on integrating AI with clinical diagnostics, utilizing a vast database for drug development and clinical trial optimization [20][21] - BGI is enhancing sequencing efficiency through AI tools and has established a significant presence in over 100 countries [32] - Other notable companies include Shengxiang Biology, Novogene, and Berry Genomics, all of which are advancing their AI capabilities in sequencing and diagnostics [34][35]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-005 成都市贝瑞和康基因技术股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"、"上市公司" 或"公司"）全资子公司福建贝瑞和康基因技术有限公司（以下简称"福建贝瑞"） 与福州滨海临空开发建设有限公司共同成立福州新投生物科技产业园建设发展 有限公司（以下简称"合资公司"）并收购福建贝瑞持有的福建产业园资产。为 保障交易顺利实施，上市公司及子公司福建贝瑞需对部分交易事项提供担保。上 市公司于 2024 年 2 月 3 日召开第十届董事会第六次会议、于 2024 年 2 月 21 日 召开 2024 年第一次临时股东大会审议通过了《关于对外担保的议案》，同意福建 贝瑞/上市公司对合资公司的担保金额不超过 19,600 万元。具体内容详见公司于 2024 年 2 月 5 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于对外担保的 公告》（公告编号：2024-006）。 近日，合 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-004 成都市贝瑞和康基因技术股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"、"本公司"） 股票于2025年3月3日、2025年3月4日连续两个交易日收盘价涨幅偏离值累计超 过20%。根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波 动。 二、公司关注并核实的相关情况 5、股票异常波动期间，控股股东、实际控制人及其一致行动人未买卖公司 股票； 6、公司不存在违反公平信息披露的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所股票上市 规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、 意向、协议等；董事会也未获悉本公司有根据《深圳证券交易所股票上市规则》 等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格产生 较大影响的信息；公司前期披露的信息不存在需要更正、补充之处。 四、相 ...

Summary of the Conference Call on Gene Sequencing and AI Big Data Company Overview - The conference was hosted by Shanxi Securities and Beirui Gene, focusing on gene sequencing and AI big data - Beirui Gene primarily engages in genetic testing, particularly in pediatrics, obstetrics, and genetics, with NIPT testing being a core business - The company has faced continuous losses in recent years, attributed to intense competition, price wars, and declining birth rates affecting its main business, which constitutes over 60% of its operations [1][2] Core Business Challenges - The AIT business is experiencing fierce competition and price reductions due to national procurement and medical insurance policies [2] - The overall birth rate is declining, impacting the demand for genetic testing services [2] - The company has been focusing on upgrading its product offerings, such as the NFTT plus product, which tests for over 100 diseases, and is working on third-generation sequencing technology [2][3] Future Development Strategies - Beirui Gene is implementing cost control measures and exploring international markets, particularly in Southeast Asia and the Middle East [3][6] - The company is collaborating with an overseas partner to develop a desktop sequencer based on third-generation sequencing technology [3] - The company aims to enhance its product offerings and market presence by leveraging advancements in AI and big data analytics [8][10] AI and Data Integration - Beirui Gene has developed a comprehensive database integrating testing data, public data, and literature data, exceeding PB levels in data volume [8] - The company is creating various AI models for genetic disease diagnosis and literature interpretation, aiming to improve efficiency in medical institutions [9][10] - Future plans include providing localized model training for hospitals and enhancing report interpretation efficiency [10][11] Market Position and Competitors - The company is benchmarking against international competitors like CDS, which has seen rapid growth in the newborn genetic disease testing market [3] - Beirui Gene is focusing on building partnerships with leading hospitals to enhance its data capabilities and service offerings [14][21] Financial Performance - The company reported a loss of approximately 200 million in 2020, primarily due to investments and accounts receivable provisions, but has maintained strong operating cash flow [7] - The gross profit margin is on an upward trend, indicating potential for future profitability [7] Regulatory and Market Environment - The company is navigating regulatory challenges related to data privacy and medical data commercialization in China [10][11] - Beirui Gene is committed to using domestic alternatives for its products, especially in light of recent geopolitical tensions affecting supply chains [5][6] Future Outlook - The company is optimistic about the potential of AI in enhancing genetic testing and predictive capabilities for diseases [16][25] - Beirui Gene is focusing on specific fields such as pediatrics and obstetrics, aiming to develop targeted AI models for these areas [21][32] - The company acknowledges the need for a robust commercial model and is exploring various avenues for growth in both B2B and B2C markets [29][36] Conclusion - Beirui Gene is positioned to leverage its data and AI capabilities to enhance its service offerings in the genetic testing market, despite facing significant challenges in competition and regulatory environments [36]

Group 1: Company Overview and Mission - Beirui Gene has focused on creating a new future in gene technology for 15 years, aiming to enhance human well-being through innovation [2] - The company operates in over 30 provinces and regions in China, as well as in Southeast Asia, the Middle East, and Australia, collaborating with over 2,000 hospitals [2] - Beirui has provided gene testing services to over 5 million individuals, alleviating economic burdens exceeding 100 billion yuan for society and families [2] Group 2: Genetic Testing and AI Integration - In the field of genetic disease testing, Beirui is developing a comprehensive diagnostic platform that offers various testing combinations for prenatal, pediatric, and adult genetic disease detection [2] - The company has built a vast medical knowledge graph by accumulating extensive experimental, research, and clinical data, which supports AI applications in healthcare [2][3] - The core value of AI in healthcare is to reconstruct the medical ecosystem, with plans to collaborate with top medical institutions for multi-omics data training [3] Group 3: Health Management Model and Data Utilization - Beirui's health management model is designed to provide rapid and accurate information on rare diseases, significantly improving decision-making efficiency [5] - The data lake contains over 10 million clinical diagnosis records and hundreds of billions of tokens, forming a knowledge graph with nearly 1 billion nodes and edges [5] - The company ensures data quality and security through strict compliance with national regulations, transforming individual data into group data for better analysis [6][7] Group 4: Collaboration and Future Projects - In January 2025, Beirui successfully delivered and tested the first batch of the Vega desktop long-read sequencing platform in collaboration with PacBio [7] - The company is accelerating the development and clinical registration of the Chinese version of the Vega CNDx model, aiming for overseas market approval [7]